Randomized Open-label Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of Afabicin IV/Oral in the Treatment of Patients With Bone or Joint Infection Due to Staphylococcus
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Afabicin (Primary) ; Afabicin (Primary) ; Cefazolin; Clindamycin; Clindamycin; Linezolid; Linezolid; Vancomycin
- Indications Bone and joint infections; Staphylococcal infections
- Focus Adverse reactions
- Sponsors Debiopharm
- 01 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 27 May 2019 Planned End Date changed from 1 Nov 2019 to 23 Jul 2020.
- 27 May 2019 Planned primary completion date changed from 1 Nov 2019 to 23 Jul 2020.